- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03775499
Probiotic BL NCC 2705 and Gluten Sensitivity
Proof of Concept Clinical Trial of Safety and Biological Activity of Bifidobacterium Longum NCC 2705 in Gluten Sensitivity
Study Overview
Status
Conditions
Detailed Description
This trial is a multicenter, double blind, randomized, placebo controlled, 2 by 2 cross-over design (i.e. 2-sequences, 2-periods, 2-treatments) for each specific population (i.e. self-reported Non Coeliac Gluten Sensitivity and Coeliac Disease subjects).
1 capsule of BL NCC 2705 or placebo will be given twice a day in the morning and in the evening with a meal over 2 periods of 4 days.
On day four a single dose of gluten (3g) will be administered and duodenal fluid will be collected in the following hours through a naso-intestinal catheter. The viability of BL NCC 2705, the production of serpin and its effects on gluten digestion and intestinal enzymatic activity will be determined.
No chronic administration of gluten as a challenge is foreseen in the study.
After a wash out period of minimum 2 weeks, period will be repeated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Venlo, Netherlands
- VieCuri Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to sign written informed consent prior to trial entry
- Male or female adults >18 years of age
- For NCGS: self-reported gluten sensitivity with negative CD serology, on gluten free diet for at least 6 weeks with self-reported significant symptomatic improvement
- For CD: confirmed serologic and histologic diagnosis of CD and on GFD for at least 12 months with self-reported significant symptomatic improvement
- Body Mass Index (BMI) within the range >18 - <30 kg/m2
- Willing and able to comply with study procedures and restrictions
- In good health as determined by a medical history and medical examination
Exclusion Criteria:
- Documented IgE-mediated food allergy
- Subjects following an overly imbalanced or restrictive diet as per nutritional advice
- Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be detrimental for the participants safety or potentially interfering with the study procedures and/or study outcomes
- Concurrent organic GI pathology other than benign polyps, diverticulosis, hemorrhoids, lipomas and melanosis coli
- Previous abdominal surgery with the exception of hernia repair, appendectomy, caesarian section, tubal ligation, hysterectomy, hemorrhoidectomy
- Patients who received antibiotics in the previous 2 weeks
- women of childbearing potential not willing to use an effective contraception method
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Period 1: Placebo - Period 2: BL NCC 2705
For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
|
2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
|
Other: Period 1: BL NCC 2705 - Period 2: Placebo
For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
|
2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence, type and severity of adverse event
Time Frame: from Baseline to end of study (up to maximum 43 days)
|
incidence, type and severity of adverse event
|
from Baseline to end of study (up to maximum 43 days)
|
Gastro-intestinal tolerability: visual analog scale
Time Frame: from Baseline to end of study (up to maximum 43 days)
|
Sum of visual analog scale for gastro-intestinal symptoms assessment (nausea, vomiting, diarrhea, audible bowel sound, flatulence and abdominal cramping symptoms are assessed).
Each scale is from 0 (no symptom) to 100mm (maximum symptom).
The maximum sum value is 600.
|
from Baseline to end of study (up to maximum 43 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of bacterial Serpin RNA and/or proteins (ng/mL) in duodenal aspirates
Time Frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Measurements via RT-PRC and immuno-assay
|
19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Concentration of Probiotic BL NCC 2705 (ng/mL) in duodenal aspirates
Time Frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Measurements via PCR
|
19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Concentration of gluten derived pepides in duodenal aspirates
Time Frame: 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in duodenal apsirates
|
10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Concentration of gluten derived pepides in urine
Time Frame: 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in urine
|
10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Level of elastase (Units/ mL) activity in duodenal aspirates
Time Frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Measurements of proteolytic activity based assay
|
19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Carmine D'Urzo, Dr., Nestec Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17.11.NRC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease
-
University of OxfordCompletedCeliac Disease | Mental Health Wellness 1 | Emotional Problem | Stigma, Social | Celiac Disease in Children | Celiac | DisclosureUnited Kingdom
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
-
Schneider Children's Medical Center, IsraelUnknownCeliac Disease in ChildrenIsrael
-
University of PalermoCompletedNot-celiac Gluten (Wheat) SensitivityItaly
-
University of PalermoRecruiting
-
University of PalermoCompletedNot-celiac Gluten SensitivityItaly
-
ASST Fatebenefratelli SaccoNot yet recruiting
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitationCeliac Disease in ChildrenNetherlands
Clinical Trials on Intervention 1 : Maltodextrin
-
National Taiwan University HospitalRecruitingGastric Cancer | Gastrostomy | ImmunonutritionTaiwan
-
Northwestern UniversityUniversity of Illinois at ChicagoActive, not recruitingParkinson Disease | Dietary Modification | Intestinal Bacteria Flora DisturbanceUnited States
-
Conselho Nacional de Desenvolvimento Científico...CompletedSigns and Symptoms, Digestive | Dyslipidemia | HIV | Dietary ModificationBrazil
-
University of MinhoFoundation for Science and Technology (FCT)Recruiting
-
University of AlbertaUniversity of British ColumbiaCompleted
-
Eunice Kennedy Shriver National Institute of Child...CompletedDiarrhea | MalnutritionPeru
-
NestléCompleted
-
University of BathUniversity of BirminghamCompleted
-
NestléCompleted
-
University of FoggiaCasa Sollievo della Sofferenza IRCCSActive, not recruitingCesarean Section ComplicationsItaly